CLINICAL NEUROSCIENCEN-acetyl-L-cysteine improves survival and preserves motor performance in an animal model of familial amyotrophic lateral sclerosisAndreassen, Ole A.1; Dedeoglu, Alpaslan1; Klivenyi, Peter1; Beal, M Flint1,2; Bush, Ashley I.3,4Author Information 1Neurochemistry Laboratory, Neurology Service, Massachusetts General Hospital and Harvard Medical School, Boston, MA 2Neurology Department, New York Hospital-Cornell Medical Center, New York, NY, USA 3Laboratory for Oxidation Biology, Genetics and Aging Unit, Massachusetts General Hospital East and Harvard Medical School, Bldg 149, 13th Street, Charlestown, MA 02129 4Corresponding Author: Ashley I. Bush Received 9 May 2000; accepted 25 May 2000 NeuroReport: August 3, 2000 - Volume 11 - Issue 11 - p 2491-2493 Buy Abstract Increasing evidence implicates oxidative damage as a major mechanism in the pathogenesis of amyotrophic lateral sclerosis (ALS). We examined the effect of preventative treatment with N-acetyl-L-cysteine (NAC), an agent that reduces free radical damage, in transgenic mice with a superoxide dismutase (SOD1) mutation (G93A), used as an animal model of familial ALS. NAC was administered at 1% concentration in the drinking water from 4–5 weeks of age. The treatment caused a significantly prolonged survival and delayed onset of motor impairment in G93A mice treated with NAC compared to control mice. These results provide further evidence for the involvement of free radical damage in the G93A mice, and support the possibility that NAC, an over-the-counter antioxidant, could be explored in clinical trials for ALS. © 2000 Lippincott Williams & Wilkins, Inc.